Abstract:CDK2, which interacts with cyclin A and cyclin E, is an important member of the CDK family. Having been proved to be associated with many diseases for its vital role in cell cycle, CDK2 is a promising target of anti-cancer drugs dealing with cell cycle disorders. In the present work, a total of 111 pyrazolo[1,5-a]pyrimidines (PHTPPs) as CDK2/cyclin A inhibitors were studied to conduct three-dimensional quantitative structure-activity (3D-QSAR) analyses. The optimal comparative molecular similarity indices analysis (CoMSIA) model shows that Q(2) = 0.516, R-ncv(2) = 0.912, R-pre(2) = 0.914, R-m(2) = 0.843, SEP = 0.812, SEE = 0.347 with 10 components using steric, hydrophobic and H-bond donor field descriptors, indicating its effective internal and external predictive capacity. The contour maps further indicate that (1) bulky substituents in R-1 are beneficial while H-bond donor groups at this position are detrimental; (2) hydrophobic contributions in the R-2 area are favorable; (3) large and hydrophilic groups are well tolerated at the R-3 position (a close H-bond donor moiety is favorable while a distal H-bond donor moiety in this area is disfavored); (4) bulky and hydrophobic features in the R-4 region are beneficial for the biological activities and (5) the 7-N-aryl substitution is crucial to boost the inhibitory activities of the PHTPP inhibitors. Finally, docking and MD simulations demostrate that PHTPP derivatives are stabilized in a 'flying bat' conformation mainly through the H-bond interactions and hydrophobic contacts. Comparative studies indicate that PHTPP derivatives fit well within the ATP binding cleft in CDK2, with the core heterocyclic ring overlapping significantly with the adenine group of ATP despite a small deflection. In comparison to numerous other inhibitors binding to the ATP pocket, PHTPP analogues follow the binding fashion of purine inhibitors of this kinase. It is anticipated that the binding mechanism and structural features of PHTPP inhibitors studied in the present work will benefit the discovery of more potent CDK2 inhibitors, and the valid pyrazolo[1,5-a]pyrimidine-7-N-yl inhibitors will soon emerge from the large number of screening programmes to enter in clinical studies.

Molecular Mechanism Concerning Conformational Changes of CDK2 Mediated by Binding of Inhibitors Using Molecular Dynamics Simulations and Principal Component Analysis

Decoding molecular mechanism of inhibitor bindings to CDK2 using molecular dynamics simulations and binding free energy calculations

Effect of Substituents in Different Positions of Aminothiazole Hinge-Binding Scaffolds on Inhibitor–CDK2 Association Probed by Interaction Entropy Method

Molecular modelling on small molecular CDK2 inhibitors: an integrated approach using a combination of molecular docking, 3D-QSAR and pharmacophore modelling.

Identification of natural marine compounds as potential inhibitors of CDK2 using molecular docking and molecular dynamics simulation approach

Molecular Principle of the Cyclin-Dependent Kinase Selectivity of 4-(Thiazol-5-yl)-2-(phenylamino) Pyrimidine-5-carbonitrile Derivatives Revealed by Molecular Modeling Studies.

Computational Analysis for Residue-Specific CDK2-Inhibitor Bindings

Insights On Structural Characteristics And Ligand Binding Mechanisms Of Cdk2

Novel structural features of CDK inhibition revealed by an ab initio computational method combined with dynamic simulations

Discovery of novel inhibitors of CDK2 using docking and physics-based binding free energy calculation

Molecular Dynamic Simulations Give Insight into the Mechanism of Binding Between 2-Aminothiazole Inhibitors and CDK5

Using 3D-QSAR and Molecular Docking Insight into Inhibitors Binding with Complex-Associated Kinases CDK8

The Interactions Between Purine-Pyrimidine Derivatives and Cdk2 Based on Molecular Dynamic Simulation

An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.

Binding Modes and Conformational Changes of FK506-binding Protein 51 Induced by Inhibitor Bindings: Insight into Molecular Mechanisms Based on Multiple Simulation Technologies

Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2/4/6

Development of in Silico Models for Pyrazoles and Pyrimidine Derivatives As Cyclin-Dependent Kinase 2 Inhibitors

Insights into the binding mechanisms of inhibitors of MDM2 based on molecular dynamics simulations and binding free energy calculations

Identification of Potential ATP-competitive Cyclin-Dependent Kinase 1 Inhibitors: De Novo Drug Generation, Molecular Docking, and Molecular Dynamics Simulation.

Exploring the prominent performance of CX-4945 derivatives as protein kinase CK2 inhibitors by a combined computational study.

Binding Mechanism of CDK5 with Roscovitine Derivatives Based on Molecular Dynamics Simulations and MM/PBSA Methods.